- Shares of KMG Chemicals, Inc. (NYSE:KMG) gained 0.3% after reporting first quarter 2018 earnings of $0.83 a share, surpassing the Zacks Consensus Estimate of $0.63
- Shares of argenx SE (NASDAQ:ARGX) rallied almost 79% after the company reported positive results from Phase 2 proof-of-concept trial of its drug ARGX-113 used in the treatment of generalized myasthenia gravis
- Blueprint Medicines Corporation’s (NASDAQ:BPMC) shares rallied 22.9% after the company reported positive new data from Phase 1 clinical trial of its drug Avapritinib
- bluebird bio, Inc.’s (NASDAQ:BLUE) shares surged 17.9% after reporting positive clinical results from Phase 1 multicenter study of LentiGlobin gene therapy used to cure sickle cell disease at the ASH2017
KMG Chemicals, Inc. (KMG): Free Stock Analysis Report
bluebird bio, Inc. (BLUE): Free Stock Analysis Report
Blueprint Medicines Corporation (BPMC): Free Stock Analysis Report
ARGENX SE-ADR (ARGX): Free Stock Analysis Report
Original post